Nabumetone
From Wikipedia, the free encyclopedia
 |
|
|
Nabumetone
|
|
| Systematic (IUPAC) name | |
| 4-(6-methoxy-2-naphthyl)-2-butanone | |
| Identifiers | |
| CAS number | |
| ATC code | M01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C15H16O2 |
| Mol. mass | 228.29 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Protein binding | > 99% (active metabolite) |
| Metabolism | Hepatic, to active metabolite 6-methoxy-2-naphthylacetic acid |
| Half life | 23 hours (active metabolite) |
| Excretion | Renal |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status |
POM |
| Routes | Oral |
Nabumetone is a non-steroidal anti-inflammatory drug of the arylalkanoic acid family (which includes diclofenac). It is manufacturered by Meda, and is available under the brand names Relafen and Relifex.
It is used to treat pain or inflammation caused by arthritis. Nabumetone works by reducing hormones that cause pain and inflammation.
It has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAID's.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
|
|||||||||||||||||||||||||||||||||||
